Hookipa Pharma (HOOK) to Release Quarterly Earnings on Thursday

Hookipa Pharma (NASDAQ:HOOK) is projected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.69) per share and revenue of $6.50 million for the quarter.

Hookipa Pharma Trading Up 1.7 %

Shares of Hookipa Pharma stock opened at $1.19 on Tuesday. Hookipa Pharma has a twelve month low of $1.11 and a twelve month high of $10.50. The stock has a market cap of $14.35 million, a price-to-earnings ratio of -0.32 and a beta of 0.71. The company has a fifty day moving average price of $1.74 and a 200 day moving average price of $2.83.

Analyst Ratings Changes

Several brokerages have recently weighed in on HOOK. HC Wainwright reaffirmed a “neutral” rating on shares of Hookipa Pharma in a research report on Friday, January 10th. Royal Bank of Canada cut Hookipa Pharma from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $48.00 to $2.00 in a report on Friday, December 20th. Finally, JMP Securities dropped their price objective on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 21st.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.